Arrowgrass Capital Partners (US)’s Prevail Therapeutics PRVL Stock Holding History
Bought
Maintained
Sold
Other funds holding PRVL
Arrowgrass Capital Partners (US)'s PRVL Position: Q3 2019 in Review
Arrowgrass Capital Partners (US) sold out of Prevail Therapeutics (PRVL) in Q3 2019, closing a stake of 50,000 shares — an estimated $660K sold.
Arrowgrass Capital Partners (US) first reported a position in PRVL in Q2 2019 and held it in 1 quarter. The position peaked at $660K in Q2 2019. 42 funds tracked by Wall St. Rank hold PRVL as of Q3 2019.
- Arrowgrass Capital Partners (US) reported no remaining Prevail Therapeutics position as of Q3 2019 after selling out during the quarter.
- Arrowgrass Capital Partners (US) sold 50,000 Prevail Therapeutics shares in Q3 2019, an estimated $660K.
- Arrowgrass Capital Partners (US) first reported a position in Prevail Therapeutics in Q2 2019 and held it in 1 quarter.
- Arrowgrass Capital Partners (US)'s Prevail Therapeutics position peaked at $660K in Q2 2019.
- 42 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q3 2019.
Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2019, filed 14 Nov 2019.